Priser
Platform
Blog
Om os
Download
JPMorgan US Growth Equity Active UCITS ETF
JPMorgan US Growth Equity Active UCITS ETF
Borsa Italiana
0

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I JPMORGAN US GROWTH EQUITY ACTIVE UCITS ETF MED ENDAVU: Køb JPMorgan US Growth Equity Active UCITS ETF ($JGRO) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i JPMorgan US Growth Equity Active UCITS ETF, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Information

Årlige omkostninger-

TickerJGRO
Hjemsted
-
Kategori-
Skats positivlisteNej
Startsdato-
Faktaark (KID)

Om

Hunan Jingfeng Pharmaceutical Co., Ltd. is a healthcare company specializing in the development, manufacturing, and distribution of pharmaceutical products. Its primary function is to research and produce a variety of prescription and over-the-counter medications, including treatments for cardiovascular diseases, digestive system conditions, and dermatological issues. The company's robust product portfolio is critical in addressing diverse healthcare needs and enhancing patient outcomes. Operating primarily within the pharmaceutical sector, Hunan Jingfeng plays a significant role in the healthcare industry by contributing to the provision of essential medications. Based in China, the company leverages advanced technological processes to ensure the quality and efficacy of its products, maintaining compliance with industry regulations. Hunan Jingfeng Pharmaceutical Co., Ltd. is a key player in the local market while also exploring opportunities for global expansion, thereby underscoring its commitment to advancing health solutions and improving access to vital drugs.

Udbytter

0,02CNH
'04
0,08CNH
'16
0,01CNH
'18
Ex-udbytte-dato23. aug. 2018
Udbytteafkast0%